You are here: Industry Insights > Humira

News List

The Coming Successor and the Ending Humira Yi/PharmaSources
March 01, 2023
On January 31, Amgen announced that its Humira (Adalimumab) biosimilar, Amjevita (adalimumab-atto), had entered into the American market officially.And Amjevita is also the first adalimumab biosimilar approved by FDA.
AbbVie’s net revenues rise 33.9% in Q2 2021 pharmaceutical-technology
August 03, 2021
The full-year 2021 GAAP diluted EPS and adjusted diluted EPS guidance updated to $6.04 to $6.14 and $12.52 to $12.62, respectively.
AbbVie's 2Q Revenue up 34% contractpharma
August 02, 2021
New immunology assets Skyrizi and Rinvoq contribute more than $1 billion of combined sales in the quarter.
Abbvie's 1Q Reveneus up 51% contractpharma
May 06, 2021
Aesthetics portfolio drives growth in the quarter with Botox Cosmetic sales up 45%.
Pfizer/BioNTech’s vaccine to touch sales of $24.8 billion by 2021: GlobalData expresspharma
April 15, 2021
Pfizer/BioNTech’s Comirnaty (tozinameran) is forecast to have peak sales of $24.8bn by 2021, which is only its second year on the market. This is a 20 per cent increase over Humira’s peak sales of $20.5 billion, suggesting that Comirnaty could be the ...
HUMIRA Receives FDA Approval to Treat Pediatric Patients with Ulcerative Colitis americanpharmaceuticalreview
March 02, 2021
AbbVie announced the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older.
Mylan, Fujifilm Kyowa Kirin Biologics Announce FDA Approval of Hulio americanpharmaceuticalreview
July 21, 2020
Mylan and Fujifilm Kyowa Kirin Biologics announced the U.S. Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp), a biosimilar to AbbVie's Humira® (adalimumab).
Top 10 Pharmaceutical Products by Sales in the 2019H1 PharmaSources/Dopine
January 13, 2020
Humira Defending the Title, Ibrutinib Having Striking Performance, while Etanercept being Eye-popping.
UCB Trial Achieves Endpoints ContractPharma
December 11, 2019
Phase III study met its co-primary and secondary endpoints demonstrating superiority of bimekizumab to Abbvie’s Humira in plaque psoriasis
China NMPA Approves Bio-Thera Solutions’ QLETLI®, A Biosimilar To Humira® (Adalimumab) bio-thera
November 08, 2019
Approval Based on Totality of Evidence Demonstrating That QLETLI® Is Biosimilar to Humira® First Approved Biosimilar From Bio-Thera's Biosimilar Portfolio.

Previous page 1 2 3 4 5 6 7 Next page